Issues of improving the management of patients with ischemic stroke on the background of atrial fibrillation
https://doi.org/10.14412/2074-2711-2022-6-115-121
Abstract
The article discusses the clinical features of cardioembolic stroke (CES). Approaches to the examination of a patient with clinical suspicion of CES are discussed within the framework of the concept of atrial cardiopathy and its main markers. The principles for choosing the timing of oral anticoagulant administration for the purpose of secondary prevention are presented. The article discusses the special aspects of direct oral anticoagulants prescription in difficult clinical situations, in particular, in elderly and senile patients, after reperfusion therapy, with the development of hemorrhagic transformation, in the presence of combined atherosclerosis, cerebral microangiopathy, anamnesis of intracerebral hemorrhage, as well as severe cognitive impairment. Approaches to the choice of oral anticoagulant in terms of purely clinical benefit are presented.
About the Authors
A. A. Kulesh
Department of neurology and medical genetics, Acad. E.A. Vagner Perm State Medical University, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
Aleksey Aleksandrovich Kulesh
614990, Perm, Petropavlovskaya St., 26
Competing Interests:
There are no conflicts of interest.
D. A. Demin
Federal Center for Cardiovascular Surgery, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
414011, Astrakhan, Pokrovskaya Rosha St., 4
Competing Interests:
There are no conflicts of interest.
References
1. Vinogradov OI, Kulesh AA, Demin DA. Ishemicheskiy insul't: diagnostika, lecheniye, reabilitatsiya i profilaktika. Rukovodstvo dlya vrachey [Ischemic stroke: diagnosis, treatment, rehabilitation and prevention. Guide for doctors]. Moscow: ID Tretyakov; 2022. 252 p. ISBN 978-5-90657-776-4 (In Russ.).
2. Zhang Z, Wang C, Xia W, et al. Efficacy and safety of mechanical thrombectomy for cardioembolic stroke: A protocol for systematic review and meta-analysis. Medicine (Baltimore). 2021 Jan 15;100(2):e24340. doi:10.1097/MD.0000000000024340
3. Kulesh AA. Difficult issues in the management of patients with atrial fibrillation: a neurologist's point of view. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2021;13(5):4-13. doi:10.14412/2074-2711-2021-5-4-13 (In Russ.).
4. Seiffge DJ, Werring DJ, Paciaroni M, et al. Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation. Lancet Neurol. 2019 Jan;18(1):117-26. doi:10.1016/S1474-4422(18)30356-9
5. Sacchetti DC, Furie KL, Yaghi S. Cardioembolic Stroke: Mechanisms and Therapeutics. Semin Neurol. 2017 Jun;37(3):326-38. doi:10.1055/s-0037-1603465
6. Kang J, Hong JH, Jang MU, et al. Cardioembolism and Involvement of the Insular Cortex in Patients with Ischemic Stroke. PLoS One. 2015 Oct 21;10(10):e0139540. doi:10.1371/journal.pone.0139540
7. Kulesh AA, Demin DA, Vinogradov OI. Pathogenetic mechanisms of ischemic stroke: from verification to secondary prevention. Consilium Medicum. 2021;23(11):792-9. doi:10.26442/20751753.2021.11.201153 (In Russ.).
8. Kamel H, Healey JS. Cardioembolic Stroke. Circ Res. 2017 Feb 3;120(3):514-26. doi:10.1161/CIRCRESAHA.116.308407
9. Kulesh AA, Kulikova SP, Drobakha VE, et al. Role of insular cortex lesions in determining the pathogenetic subtype of ischemic stroke. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2022;14(2):11-7. doi:10.14412/2074-2711-2022-2-11-17 (In Russ.).
10. Kang DW, Jeong HG, Kim DY, et al. Prediction of Stroke Subtype and Recanalization Using Susceptibility Vessel Sign on SusceptibilityWeighted Magnetic Resonance Imaging. Stroke. 2017 Jun;48(6):1554-9. doi:10.1161/STROKEAHA.116.016217. Epub 2017 Apr 21.
11. Arboix A, Aliо J. Cardioembolic stroke: clinical features, specific cardiac disorders and prognosis. Curr Cardiol Rev. 2010 Aug;6(3):150-61. doi:10.2174/157340310791658730
12. Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2021 Jul;52(7):e364-e467. doi:10.1161/STR.0000000000000375
13. Kulesh AA, Demin DA, Vinogradov OI. Cryptogenic stroke. Part 1: Aorto-arterial embolism. Meditsinskiy sovet = Medical Council. 2021;(4):78-87. doi:10.21518/2079-701X-2021-4-78-87 (In Russ.).
14. Kulesh AA, Demin DA, Belopasova AV, et al. Cryptogenic stroke. Part 2: paradoxical embolism. Meditsinskiy sovet = Medical Council. 2021;(19):16-33. doi:10.21518/2079-701X-2021-19-16-33 (In Russ.).
15. Demin DA, Kulesh AA, Yanishevskiy SN, et al. Cryptogenic stroke. Part 3: atrial cardiopathy and silent atrial fibrillation. Meditsinskiy sovet = Medical Council. 2022;(21):8-18. doi:10.21518/2079-701X-2022-16-21-8-18 (In Russ.).
16. Poli S, Diedler J, Härtig F, et al. Insertable cardiac monitors after cryptogenic stroke – a risk factor based approach to enhance the detection rate for paroxysmal atrial fibrillation. Eur J Neurol. 2016 Feb;23(2):375-81. doi:10.1111/ene.12843
17. Hart RG, Coull BM, Hart D. Early recurrent embolism associated with nonvalvular atrial fibrillation: a retrospective study. Stroke. 1983 SepOct;14(5):688-93. doi:10.1161/01.str.14.5.688
18. Muscari A, Faccioli L, Lega MV, et al. Predicting hemorrhagic transformation and its timing from maximum cerebral lesion diameter in nonlacunar ischemic strokes. Brain Behav. 2020 Jan;10(1):e01497. doi:10.1002/brb3.1497
19. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016 Nov;18(11):1609-78. doi:10.1093/europace/euw295
20. Eun MY, Kim JY, Hwang YH, et al. Initiation of Guideline-Matched Oral Anticoagulant in Atrial Fibrillation-Related Stroke. J Stroke. 2021 Jan;23(1):113-23. doi:10.5853/jos.2020.03440
21. Hindricks G, Potpara T, Dagres N, et al.; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for CardioThoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021 Feb 1;42(5):373-498. doi:10.1093/eurheartj/ehaa612
22. Paciaroni M, Agnelli G, Falocci N, et al. Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non-Vitamin-K Oral Anticoagulants (RAF-NOACs) Study. J Am Heart Assoc. 2017 Nov 29;6(12):e007034. doi:10.1161/JAHA.117.007034
23. Yaghi S, Trivedi T, Henninger N, et al. Anticoagulation Timing in Cardioembolic Stroke and Recurrent Event Risk. Ann Neurol. 2020 Oct;88(4):807-16. doi:10.1002/ana.25844
24. Kimura S, Toyoda K, Yoshimura S, et al; SAMURAI, RELAXED, RAF, RAF-NOAC, CROMIS-2, NOACISP LONGTERM, Erlangen Registry and Verona Registry Investigators. Practical “1-2-3-4-Day” Rule for Starting Direct Oral Anticoagulants After Ischemic Stroke With Atrial Fibrillation: Combined Hospital-Based Cohort Study. Stroke. 2022 Feb 2:STROKEAHA121036695. doi:10.1161/STROKEAHA.121.036695
25. Oldgren J, Asberg S, Hijazi Z, et al; National TIMING Collaborators. Early Versus Delayed Non-Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study. Circulation. 2022 Oct 4;146(14):1056-66. doi:10.1161/CIRCULATIONAHA.122.060666
26. Vannucchi V, Moroni F, Grifoni E, et al. Management of oral anticoagulation in very old patients with non valvular atrial fibrillation related acute ischemic stroke. J Thromb Thrombolysis. 2020 Jan;49(1):86-93. doi:10.1007/s11239-019-01972-0
27. Giustozzi M, Acciarresi M, Agnelli G, et al. Safety of Anticoagulation in Patients Treated With Urgent Reperfusion for Ischemic Stroke Related to Atrial Fibrillation. Stroke. 2020 Aug;51(8):2347-54. doi:10.1161/STROKEAHA.120.030143
28. Paciaroni M, Bandini F, Agnelli G, et al. Hemorrhagic Transformation in Patients With Acute Ischemic Stroke and Atrial Fibrillation: Time to Initiation of Oral Anticoagulant Therapy and Outcomes. J Am Heart Assoc. 2018 Nov 20;7(22):e010133. doi:10.1161/JAHA.118.010133
29. Katsi V, Georgiopoulos G, Skafida A, et al. Noncardioembolic Stroke in Patients with Atrial Fibrillation. Angiology. 2019 Apr;70(4):299-304. doi:10.1177/0003319718791711
30. Wilson D, Ambler G, Lee KJ, et al; Microbleeds International Collaborative Network. Cerebral microbleeds and stroke risk after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from cohort studies. Lancet Neurol. 2019 Jul;18(7):653-65. doi:10.1016/S1474-4422(19)30197-8
31. Guo Z, Ding X, Ye Z, et al. Non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists in atrial fibrillation patients with previous stroke or intracranial hemorrhage: A systematic review and meta-analysis of observational studies. Clin Cardiol. 2021 Jul;44(7):917-24. doi:10.1002/clc.23647
32. Banerjee A, Benedetto V, Gichuru P, et al. Adherence and persistence to direct oral anticoagulants in atrial fibrillation: a population-based study. Heart. 2020 Jan;106(2):119-26. doi:10.1136/heartjnl-2019-315307
33. Ozaki AF, Choi AS, Le QT, et al. Real-World Adherence and Persistence to Direct Oral Anticoagulants in Patients With Atrial Fibrillation: A Systematic Review and MetaAnalysis. Circ Cardiovasc Qual Outcomes. 2020 Mar;13(3):e005969. doi:10.1161/CIRCOUTCOMES.119.005969
34. Kulesh AA. Net clinical benefit of anticoagulant therapy from a neurologist's perspective: A review. Consilium Medicum. 2022;24(2):79-84. doi:10.26442/20751753.2022.2.201537 (In Russ.).
35. Banerjee A, Lane DA, Torp-Pedersen C, Lip GY. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost. 2012 Mar;107(3):584-9. doi:10.1160/TH11-11-0784
36. Renda G, di Nicola M, De Caterina R. Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials. Am J Med. 2015 Sep;128(9):1007-14.e2. doi:10.1016/j.amjmed.2015.03.034
37. Hsu JC, Hsieh CY, Yang YH, Lu CY. Net clinical benefit of oral anticoagulants: a multiple criteria decision analysis. PLoS One. 2015 Apr 21;10(4):e0124806. doi:10.1371/journal.pone.0124806
38. Ntaios G, Papavasileiou V, Makaritsis K, et al. Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis. Stroke. 2017 Sep;48(9):2494-503. doi:10.1161/STROKEAHA.117.017549
39. Amin A, Keshishian A, Dina O, et al. Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population. J Thromb Thrombolysis. 2019 Aug;48(2):240-9. doi:10.1007/s11239-019-01838-5
40. Esteve-Pastor MA, Rivera-Caravaca JM, Roldan V, et al. Estimated Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants Compared With Optimally Acenocoumarol Anticoagulated “Real-World” in Patients With Atrial Fibrillation. Am J Cardiol. 2018 Sep 1;122(5):785-92. doi:10.1016/j.amjcard.2018.05.012
Review
For citations:
Kulesh AA, Demin DA. Issues of improving the management of patients with ischemic stroke on the background of atrial fibrillation. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2022;14(6):115-121. (In Russ.) https://doi.org/10.14412/2074-2711-2022-6-115-121
Views: 312
Email this article 